Trial · NCT03686488
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 96
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | TAS 102 and Ramucirumab | 13 | 23 | 15 |
| other | Nausea | Gastrointestinal disorders | TAS 102 and Ramucirumab | 13 | 23 | 15 |
| other | Vomiting | Gastrointestinal disorders | TAS 102 and Ramucirumab | 12 | 23 | 15 |
| other | Constipation | Gastrointestinal disorders | TAS 102 and Ramucirumab | 6 | 23 | 6 |
| other | Gastrointestinal disorders -Other | Gastrointestinal disorders | TAS 102 and Ramucirumab | 5 | 23 | 6 |
| other | Abdominal pain | Gastrointestinal disorders | TAS 102 and Ramucirumab | 4 | 23 | 9 |
| other | Toothache | Gastrointestinal disorders | TAS 102 and Ramucirumab | 3 | 23 | 3 |
| other | Ascites | Gastrointestinal disorders | TAS 102 and Ramucirumab | 2 | 23 | 2 |
| other | Dysphagia | Gastrointestinal disorders | TAS 102 and Ramucirumab | 2 | 23 | 2 |
| other | Dental caries | Gastrointestinal disorders | TAS 102 and Ramucirumab | 1 | 23 | 2 |
| other | Dry mouth | Gastrointestinal disorders | TAS 102 and Ramucirumab | 1 | 23 | 1 |
| other | Dyspepsia | Gastrointestinal disorders | TAS 102 and Ramucirumab | 1 | 23 | 1 |
| other | Hemorrhoids | Gastrointestinal disorders | TAS 102 and Ramucirumab | 1 | 23 | 1 |
| other | Oral hemorrhage | Gastrointestinal disorders | TAS 102 and Ramucirumab | 1 | 23 | 1 |
| other | Stomach pain | Gastrointestinal disorders | TAS 102 and Ramucirumab | 1 | 23 | 1 |
| other | Upper gastrointestinal hemorrhage | Gastrointestinal disorders | TAS 102 and Ramucirumab | 1 | 23 | 1 |
| other | Fatigue | General disorders | TAS 102 and Ramucirumab | 14 | 23 | 16 |
| other | General disorders and administration site conditions - Other | General disorders | TAS 102 and Ramucirumab | 5 | 23 | 7 |
| other | Chills | General disorders | TAS 102 and Ramucirumab | 4 | 23 | 5 |
| other | Pain | General disorders | TAS 102 and Ramucirumab | 4 | 23 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03686488/events